The treatment landscape for EGFR-mutated non small cell lung cancer continues to evolve. In February 2026, the U.S. Food and Drug Administration approved a new once monthly dosing schedule for Rybrevant Faspro, marking a significant milestone for patients with advanced non small cell lung cancer.
Developed by Johnson & Johnson, this update allows eligible patients receiving Rybrevant Faspro in combination with Lazcluze to transition to monthly injections beginning at Week 5 of treatment. The new schedule maintains efficacy and safety outcomes while reducing the number of clinic visits required.
This blog explores what the approval means, how the therapy works, the clinical trial evidence behind the decision, safety considerations, and what patients and caregivers should know.
Non small cell lung cancer, often abbreviated as NSCLC, accounts for approximately 80 to 85 percent of all lung cancer cases worldwide. According to the World Health Organization and the American Cancer Society, lung cancer remains one of the most commonly diagnosed cancers globally.
A significant subset of NSCLC patients have tumors driven by mutations in the epidermal growth factor receptor, or EGFR. These mutations lead to uncontrolled tumor cell growth. EGFR exon 19 deletions and exon 21 L858R substitution mutations are among the most common forms.
Despite advances in EGFR targeted therapies, long term outcomes remain challenging. Five year survival rates for advanced EGFR-mutated NSCLC treated with earlier generation EGFR tyrosine kinase inhibitors remain below 20 percent in many studies. Resistance mechanisms such as MET amplification and secondary EGFR mutations continue to limit durable disease control.
This is where combination strategies such as amivantamab plus lazertinib aim to make a difference.
Rybrevant Faspro is a subcutaneous formulation of amivantamab, a fully human bispecific antibody that targets both EGFR and MET pathways. It is co formulated with recombinant human hyaluronidase to enable subcutaneous delivery.
The intravenous version, Rybrevant, was already approved for multiple EGFR-mutated NSCLC indications. The subcutaneous formulation was designed to significantly reduce administration time compared to intravenous infusion.
By switching from intravenous infusion to subcutaneous injection, treatment time was reduced from hours to minutes. Clinical data also showed a fivefold reduction in administration related reactions compared to historical intravenous data.
With the new FDA approval, patients can now receive this therapy once monthly after completing initial weekly doses during Weeks 1 through 4.
The U.S. Food and Drug Administration approved a simplified once monthly dosing schedule for Rybrevant Faspro when used in combination with Lazcluze as first line therapy for:
The approval confirms that monthly dosing delivers consistent pharmacokinetics, efficacy, and safety compared with the previously approved every two week subcutaneous schedule.
Patients may transition to monthly injections starting at Week 5. Weekly injections are administered during the first four weeks of therapy.
This adjustment aims to reduce clinic visits while maintaining the established clinical benefit seen in earlier trials.
The PALOMA-2 Phase 2 study evaluated subcutaneous amivantamab administered every four weeks in combination with lazertinib in patients with previously untreated EGFR-mutated advanced NSCLC.
Key findings presented at the 2025 World Conference on Lung Cancer demonstrated:
The trial confirmed that monthly dosing does not compromise therapeutic effectiveness.
The larger Phase 3 MARIPOSA study compared amivantamab plus lazertinib versus osimertinib in the first line treatment setting.
The combination demonstrated significant improvements in progression free survival and overall survival compared with standard therapy in certain patient populations. Importantly, analyses presented at international lung cancer conferences showed reduced rates of acquired resistance mechanisms such as:
These findings support the biologic rationale behind dual EGFR and MET targeting.
Frequent oncology visits can be physically and emotionally taxing. Monthly dosing may:
For patients balancing work, family responsibilities, and treatment, fewer visits can make a meaningful difference.
In clinical trials, administration related reactions with subcutaneous dosing occurred in approximately 12 to 13 percent of patients, compared to 66 percent historically with intravenous administration.
Venous thromboembolic events were consistent with biweekly dosing and significantly lower than historical intravenous data without anticoagulation.
No new safety signals were identified with monthly dosing.
Like all oncology therapies, Rybrevant Faspro carries important risks.
Symptoms may include:
Premedication with antihistamines, antipyretics, and glucocorticoids is recommended.
Severe and potentially fatal interstitial lung disease has been reported. Patients should be monitored for:
Immediate evaluation is required if symptoms occur.
When combined with Lazcluze, the therapy may increase the risk of blood clots. Prophylactic anticoagulation during the first four months of therapy is recommended in many cases.
Rash is one of the most common side effects, occurring in up to 80 percent or more of patients in some studies. Preventive skin care strategies and early dermatologic consultation are encouraged.
Eye related side effects such as keratitis and blurred vision have been reported. Prompt referral to an ophthalmologist is recommended if symptoms develop.
Patients should review the full prescribing information and discuss risks with their oncology care team.
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology include amivantamab based regimens as a Category 1 preferred option in certain first line EGFR-mutated NSCLC settings.
The guidelines also recognize the substitution of subcutaneous amivantamab for intravenous administration when appropriate.
Guideline inclusion supports the clinical adoption of this combination in routine practice.
Rybrevant is a first in class bispecific antibody that:
Lazcluze is a third generation EGFR tyrosine kinase inhibitor designed to penetrate the brain and target both activating mutations and the T790M resistance mutation.
Together, the combination aims to:
By addressing multiple resistance pathways simultaneously, researchers hope to alter the natural history of EGFR-mutated NSCLC.
Rybrevant Faspro has been approved in multiple international markets, including:
The legal manufacturer of Rybrevant is Janssen Biotech, Inc., a Johnson & Johnson company.
Johnson & Johnson offers the Rybrevant withMe program to assist patients with:
Such programs may help eligible patients access therapy more efficiently.
Resistance to third generation EGFR inhibitors such as osimertinib has remained a central challenge in lung cancer care. The combination of amivantamab plus lazertinib represents a new strategy that directly addresses both EGFR and MET mediated resistance pathways.
The approval of monthly dosing reflects a broader oncology trend toward patient centered care models that prioritize:
As additional long term survival data emerge, oncologists will gain further clarity on how best to sequence and combine targeted therapies in this setting.
Johnson & Johnson press release announcing FDA approval of monthly dosing for Rybrevant Faspro, February 17, 2026.
This article is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or treatment options.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.